 |
||||||||
|
Orchid Chemicals & Pharmaceuticals Ltd |
||||||||
|
Audited Financial Results for the year ended
March 31, 2005
|
||||||||
| Sl No |
Particulars
|
Nine months ended
31-Dec-04 (unaudited) |
Three Months ended
31-Mar-05 (unaudited) |
Three
Months ended
31-Mar-04 (unaudited)
|
Year ended
31-Mar-05 (Audited)
|
Year ended
31-Mar-04 (Audited)
|
Consolidated Accounts
31-Mar-05 (Audited)
|
Consolidated Accounts
31-Mar-04 (Audited)
|
|
1
|
Sales and Operating Income |
51118.95
|
17810.49
|
20775.18
|
68929.44
|
71340.98 |
73474.52
|
69931.94
|
|
2
|
Other Income |
63.40
|
18.84
|
19.41
|
82.24
|
123.12
|
86.81
|
124.61
|
|
3
|
Total Expenditure |
39024.29
|
13676.42
|
16646.15
|
52700.71
|
56415.00
|
57785.30
|
55540.89
|
|
a) Decrease/(Increase) in Stock in trade |
(4362.80)
|
(5475.15)
|
(801.37)
|
(9837.95)
|
(4387.75)
|
(10467.95)
|
(5072.55)
|
|
| b) Consumption of raw materials |
26970.13
|
12430.37
|
11089.58
|
39400.50
|
39355.45
|
43818.77
|
38993.61
|
|
| c) Staff Cost |
4096.85
|
1341.24
|
1478.63
|
5438.09
|
4841.60
|
5548.59
|
4841.60
|
|
| d) Other Expenditure |
12320.11
|
5379.96
|
4879.31
|
17700.07
|
16605.70
|
18885.89
|
16778.23
|
|
|
4
|
Profit before Interest, Depreciation & Tax
(1+2-3)
|
12158.06
|
4152.91
|
4148.44
|
16310.97
|
15049.10
|
15776.03
|
14515.66
|
|
5
|
Interest and Finance Charges |
5372.57
|
1858.43
|
1655.42
|
7231.00
|
6067.08
|
7354.58
|
6093.77
|
|
6
|
Depreciation |
4635.50
|
1553.70
|
1665.81
|
6189.20
|
5684.23
|
6335.76
|
5724.52
|
|
7
|
Profit before tax |
2149.99
|
740.78
|
827.21
|
2890.77
|
3297.79
|
2085.69
|
2697.37
|
|
8
|
Provision for Taxation |
|
|
|
|
|||
| - Current Tax |
137.77
|
56.83
|
51.90
|
194.60
|
195.00
|
194.60
|
195.00
|
|
| - Deferred Tax |
570.81
|
(975.74)
|
(404.93)
|
(404.93)
|
||||
|
9
|
Net Profit (7-8) |
1441.41
|
1659.69
|
775.31
|
3101.10
|
3102.79
|
2296.02
|
2502.37
|
|
10
|
Paid- up Equity Share Capital (Face value of Rs. 10 each) |
3238.19
|
3413.19
|
3238.19
|
3413.19
|
3238.19
|
3413.19
|
3238.19
|
|
11
|
Reserves excluding Revaluation Reserves |
|
|
|
43714.20
|
38631.68
|
42883.64
|
37794.19
|
|
12
|
Basic Earnings per Share (EPS) Rs. |
4.45*
|
5.06*
|
2.39*
|
9.55*
|
9.58
|
7.07*
|
7.73
|
|
13
|
Diluted Earnings per share (EPS) Rs.
|
4.21*
|
4.83*
|
2.39*
|
9.05*
|
9.58
|
6.70*
|
7.73
|
| 14 |
Aggregate of Non-Promoter Shareholding |
27495965 |
27704462 |
|||||
|
80.56
|
85.56
|
|||||||
| *EPS is for the period (not annualised) after providing for taxes | ||||||||
| SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED | ||||||||||
|
(Rs.Lakhs)
|
||||||||||
|
Particulars
|
Nine months ended
31-Dec-04 |
Three months ended
31-Mar-05 |
Three Months ended 31-Mar-04
|
Year ended
31-Mar-05
|
Year ended
31-Mar-04
|
Consolidated Accounts
31-Mar-05
|
Consolidated Accounts
31-Mar-04
|
|||
| 1. Segment Revenue |
|
|
|
|||||||
| a. Bulk |
44314.38
|
15778.30
|
18256.52
|
60092.68
|
62455.23
|
64637.76
|
62786.85
|
|||
| b. Formulations |
7147.42
|
2472.78
|
2525.20
|
9620.20
|
10441.13
|
9620.20
|
10441.13
|
|||
| Total |
51461.80
|
18251.08
|
20781.72
|
69712.88
|
72896.36
|
74257.96
|
73227.98
|
|||
| Less: Inter segment revenue |
342.85
|
440.59
|
6.54
|
783.44
|
1555.38
|
783.44
|
3296.04
|
|||
| Net Sales / Income from Operations |
51118.95
|
17810.49
|
20775.18
|
68929.44
|
71340.98
|
73474.52
|
69931.94
|
|||
|
|
|
|
|
|
||||||
| 2. Segment Results: Profit/(Loss) before interest & Tax |
|
|
|
|
|
|||||
| a. Bulk |
7819.22
|
2180.68
|
2822.22
|
9999.91
|
9546.72
|
9313.82
|
8939.71
|
|||
| b. Formulations |
(360.06)
|
399.69
|
(390.02)
|
39.63
|
(128.57)
|
39.63
|
(128.57)
|
|||
| Total |
7459.16
|
2580.37
|
2432.20
|
10039.54
|
9418.15
|
9353.45
|
8811.14
|
|||
|
|
|
|
|
|
||||||
| Less: i) Interest (Net) |
5372.57
|
1858.43
|
1655.42
|
7231.00
|
6067.08
|
7354.58
|
6093.77
|
|||
| ii) Other unallocable expenditure net off unallocable income |
(63.40)
|
(18.84)
|
(50.43)
|
(82.24)
|
53.28
|
(86.81)
|
20.00
|
|||
| Total Profit Before Tax |
2149.99
|
740.78
|
827.21
|
2890.77
|
3297.79
|
2085.69
|
2697.37
|
|||
|
|
|
|
|
|
||||||
| 3. Capital Employed |
|
|
|
|
|
|||||
| a. Bulk |
124042.52
|
127905.09
|
106458.81
|
127905.09
|
106458.81
|
136000.08
|
109160.74
|
|||
| b. Formulations |
20276.50
|
21739.24
|
15737.57
|
21739.24
|
15737.57
|
21739.24
|
15737.57
|
|||
| Total |
144319.02
|
149644.33
|
122196.38
|
149644.33
|
122196.38
|
157739.32
|
124898.31
|
|||
| * EPS is for the period (not annualised) after providing for deferred tax. | ||||||||||
| 1 | The above financial results were adopted by the Board of Directors at its meeting held on Wednesday, April 27, 2005. | |||||||||
| 2 | The Board of Directors have recommended a dividend of 40% (Rs 4/-per share) on the equity share of Rs 10 each. | |||||||||
| 3 | The Allotment Committee of
the Board have allotted shares as follows: - 17,50,000 shares to Promoter / Promoter Group on March 1, 2005 at a price of Rs.212.18 per share on conversion of warrants - 11,800 shares (8250 shares at Rs.243.35 per share and 3550 shares at Rs.252/- per share) to employees under ESOP 1999 Scheme, on April 27, 2005. |
|||||||||
| 4 | The Compensation Committee of the Board in its meeting held on April 27, 2005 approved the issue of 292075 stock options to employees. The stock options are convertible into equity shares of Rs. 10/- each at a price of Rs. 300.65 per share. | |||||||||
| 5 | During the year Orchid Pharmaceuticals Inc.USA and Gene Arrays Inc.,USA became subsidiaries of the Company. | |||||||||
| 6 | The Company received 12 complaints during the quarter ended March 31, 2005 from the shareholders. All the complaints have been resolved and no complaints were pending as on March 31, 2005. | |||||||||
| 7 | Previous period figures have been regrouped wherever necessary. | |||||||||
|
||||||||||